Avalyn Pharma (NASDAQ:AVLN) Trading 9.3% Higher – Here’s Why

Avalyn Pharma Inc. (NASDAQ:AVLN)’s stock price shot up 9.3% during trading on Wednesday . The company traded as high as $31.14 and last traded at $30.68. 206,809 shares were traded during trading, a decline of 35% from the average session volume of 316,451 shares. The stock had previously closed at $28.07.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AVLN. Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $52.00 target price on the stock. Morgan Stanley began coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 target price on the stock. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Evercore began coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 target price on the stock. Finally, Guggenheim initiated coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $80.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $59.00.

Avalyn Pharma Stock Up 8.7%

Avalyn Pharma (NASDAQ:AVLN) last posted its quarterly earnings data on Wednesday, June 3rd. The company reported ($21.83) EPS for the quarter, missing the consensus estimate of ($16.38) by ($5.45).

Insider Buying and Selling at Avalyn Pharma

In other Avalyn Pharma news, Director Jill Carroll bought 277,778 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the transaction, the director directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 14.55% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was purchased at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the transaction, the insider owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 34.06% increase in their position. The SEC filing for this purchase provides additional information.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.